A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this proposed research study is to evaluate the safety of
intravitreal ranibizumab in combination with intravitreal dexamethasone in comparison to
intravitreal ranibizumab alone in the treatment of wet ARMD. The addition of the broad
spectrum anti-inflammatory activity of dexamethasone may augment the anti-VEGF activity of
ranibizumab by amelioration of inflammation existing in the microenvironment of the choroidal
neovascularization. While the anti-VEGF agents have proven to be very efficacious in the
treatment of exudative ARMD, their narrow target and window of activity may limit their
overall durability of action.